AU2022275786C1 - Extended, high dose VEGF antagonist regimens for treatment of angiogenic eye disorders - Google Patents

Extended, high dose VEGF antagonist regimens for treatment of angiogenic eye disorders

Info

Publication number
AU2022275786C1
AU2022275786C1 AU2022275786A AU2022275786A AU2022275786C1 AU 2022275786 C1 AU2022275786 C1 AU 2022275786C1 AU 2022275786 A AU2022275786 A AU 2022275786A AU 2022275786 A AU2022275786 A AU 2022275786A AU 2022275786 C1 AU2022275786 C1 AU 2022275786C1
Authority
AU
Australia
Prior art keywords
aflibercept
dose
week
weeks
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2022275786A
Other languages
English (en)
Other versions
AU2022275786A8 (en
AU2022275786B2 (en
AU2022275786A1 (en
Inventor
Friedrich Asmus
Alyson J. BERLINER
Karen Chu
Sergio Casimiro DA SILVA LEAL
Thomas Eissing
Kay D. Rittenhouse
Robert L. Vitti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Healthcare LLC
Regeneron Pharmaceuticals Inc
Original Assignee
Bayer Healthcare LLC
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare LLC, Regeneron Pharmaceuticals Inc filed Critical Bayer Healthcare LLC
Publication of AU2022275786A1 publication Critical patent/AU2022275786A1/en
Publication of AU2022275786A8 publication Critical patent/AU2022275786A8/en
Publication of AU2022275786B2 publication Critical patent/AU2022275786B2/en
Priority to AU2025226774A priority Critical patent/AU2025226774A1/en
Application granted granted Critical
Publication of AU2022275786C1 publication Critical patent/AU2022275786C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AU2022275786A 2021-05-17 2022-05-16 Extended, high dose VEGF antagonist regimens for treatment of angiogenic eye disorders Active AU2022275786C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025226774A AU2025226774A1 (en) 2021-05-17 2025-09-04 Extended, high dose VEGF antagonist regimens for treatment of angiogenic eye disorders

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163189541P 2021-05-17 2021-05-17
US63/189,541 2021-05-17
US202163235398P 2021-08-20 2021-08-20
US63/235,398 2021-08-20
US202263297420P 2022-01-07 2022-01-07
US63/297,420 2022-01-07
US202263306315P 2022-02-03 2022-02-03
US63/306,315 2022-02-03
PCT/US2022/029462 WO2022245739A1 (en) 2021-05-17 2022-05-16 Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025226774A Division AU2025226774A1 (en) 2021-05-17 2025-09-04 Extended, high dose VEGF antagonist regimens for treatment of angiogenic eye disorders

Publications (4)

Publication Number Publication Date
AU2022275786A1 AU2022275786A1 (en) 2023-04-06
AU2022275786A8 AU2022275786A8 (en) 2023-04-20
AU2022275786B2 AU2022275786B2 (en) 2025-06-05
AU2022275786C1 true AU2022275786C1 (en) 2025-12-11

Family

ID=81975181

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2022275786A Active AU2022275786C1 (en) 2021-05-17 2022-05-16 Extended, high dose VEGF antagonist regimens for treatment of angiogenic eye disorders
AU2025226774A Pending AU2025226774A1 (en) 2021-05-17 2025-09-04 Extended, high dose VEGF antagonist regimens for treatment of angiogenic eye disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025226774A Pending AU2025226774A1 (en) 2021-05-17 2025-09-04 Extended, high dose VEGF antagonist regimens for treatment of angiogenic eye disorders

Country Status (23)

Country Link
US (1) US20230302085A1 (https=)
EP (2) EP4647125A3 (https=)
JP (1) JP2024519629A (https=)
KR (1) KR20240008821A (https=)
AU (2) AU2022275786C1 (https=)
BR (1) BR112023023002A2 (https=)
CA (1) CA3190663A1 (https=)
CL (3) CL2023003396A1 (https=)
DK (1) DK4185318T3 (https=)
ES (1) ES3041647T3 (https=)
FI (1) FI4185318T3 (https=)
HR (1) HRP20251282T8 (https=)
IL (1) IL308505A (https=)
JO (1) JOP20230283A1 (https=)
LT (1) LT4185318T (https=)
MX (1) MX2023013554A (https=)
PE (1) PE20240922A1 (https=)
PL (1) PL4185318T3 (https=)
PT (1) PT4185318T (https=)
RS (1) RS67369B1 (https=)
SI (1) SI4185318T1 (https=)
TW (1) TW202313095A (https=)
WO (1) WO2022245739A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK4364724T3 (da) 2018-05-10 2025-12-22 Regeneron Pharma Formuleringer med høj koncentration af VEGF-receptorfusionsprotein
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
IL315347A (en) * 2022-03-15 2024-11-01 Regeneron Pharma Prolonged high-dose VEGF antagonist regimens for the treatment of angiogenic ocular disorders
IL315374A (en) * 2022-03-15 2024-11-01 Regeneron Pharma Prolonged high-dose VEGF antagonist regimens for the treatment of angiogenic ocular disorders
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
CN121712520A (zh) * 2023-06-23 2026-03-20 瑞泽恩制药公司 用于治疗血管生成性眼病的延长的高剂量vegf拮抗剂方案
US20260055171A1 (en) 2024-06-11 2026-02-26 Regeneron Pharmaceuticals, Inc. Vegf antagonists and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012097019A1 (en) * 2011-01-13 2012-07-19 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist to treat angiogenic eye disorders
US20180298092A1 (en) * 2014-11-07 2018-10-18 Novartis Ag Methods for treating ocular diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
FI117667B (fi) * 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
AR046510A1 (es) 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
EP1767546B1 (en) 2004-06-08 2012-03-07 Chengdu Kanghong Biotechnologies Co., Ltd. Angiogenesis-inhibiting chimeric protein and the use
CN100502945C (zh) 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Vegf受体融合蛋白在治疗眼睛疾病中的应用
AU2012212047A1 (en) * 2011-02-03 2013-08-22 Xoma Technology Ltd. Methods and materials for enhancing functional protein expression in bacteria
CA3010862A1 (en) * 2016-01-08 2017-07-13 Clearside Biomedical, Inc. Methods and devices for treating posterior ocular disorderswith aflibercept and other biologics
HUE059827T2 (hu) * 2017-11-30 2023-01-28 Regeneron Pharma VEGF-antagonista alkalmazása angiogén szembetegségek kezelésére
CN117138171A (zh) 2017-12-13 2023-12-01 里珍纳龙药品有限公司 用于精确剂量输送的装置和方法
DK4364724T3 (da) * 2018-05-10 2025-12-22 Regeneron Pharma Formuleringer med høj koncentration af VEGF-receptorfusionsprotein
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
US20220306732A1 (en) * 2019-09-12 2022-09-29 Lupin Limited Modified dosing of vegf inhibitors for ophthalmic use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012097019A1 (en) * 2011-01-13 2012-07-19 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist to treat angiogenic eye disorders
US20180298092A1 (en) * 2014-11-07 2018-10-18 Novartis Ag Methods for treating ocular diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
REGENERON PHARMACEUTICALS: "Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration. NCT04126317", 15 October 2019 (2019-10-15), pages 1 - 8 *

Also Published As

Publication number Publication date
KR20240008821A (ko) 2024-01-19
BR112023023002A2 (pt) 2024-01-23
FI4185318T3 (fi) 2025-10-13
AU2022275786A8 (en) 2023-04-20
AU2022275786B2 (en) 2025-06-05
EP4185318B1 (en) 2025-09-03
JOP20230283A1 (ar) 2023-11-06
HRP20251282T8 (hr) 2025-12-19
MX2023013554A (es) 2023-11-29
PT4185318T (pt) 2025-09-29
CL2025001269A1 (es) 2025-08-22
EP4647125A3 (en) 2026-01-28
EP4185318A1 (en) 2023-05-31
PE20240922A1 (es) 2024-04-30
PL4185318T3 (pl) 2026-01-12
WO2022245739A1 (en) 2022-11-24
LT4185318T (lt) 2025-11-10
DK4185318T3 (da) 2025-09-29
SI4185318T1 (sl) 2025-10-30
HRP20251282T1 (hr) 2025-12-05
CA3190663A1 (en) 2022-11-24
IL308505A (en) 2024-01-01
EP4647125A2 (en) 2025-11-12
JP2024519629A (ja) 2024-05-21
RS67369B1 (sr) 2025-11-28
CL2023003396A1 (es) 2024-06-07
ES3041647T3 (en) 2025-11-13
AU2025226774A1 (en) 2025-09-25
TW202313095A (zh) 2023-04-01
CL2024002972A1 (es) 2025-01-24
US20230302085A1 (en) 2023-09-28
AU2022275786A1 (en) 2023-04-06

Similar Documents

Publication Publication Date Title
AU2022275786C1 (en) Extended, high dose VEGF antagonist regimens for treatment of angiogenic eye disorders
US20250268983A1 (en) Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders
US20230295266A1 (en) Extended, High Dose VEGF Antagonist Regimens for Treatment of Angiogenic Eye Disorders
US20240024420A1 (en) Extended, High Dose VEGF Antagonist Regimens for Treatment of Angiogenic Eye Disorders
HK40094129A (en) Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
HK40094129B (en) Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
US20250025531A1 (en) Extended, High Dose VEGF Antagonist Regimens for Treatment of Angiogenic Eye Disorders
EA051980B1 (ru) Расширенные схемы применения высоких доз антагониста vegf для лечения ангиогенных нарушений со стороны глаза
HK40099476A (en) Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
HK40099475A (en) Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
HK40119109A (en) Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
CA3190733A1 (en) Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
CA3190726A1 (en) Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
CN117642175A (zh) 用于治疗血管生成性眼病的延长的高剂量vegf拮抗剂方案

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 57 , NO 13 , PAGE(S) 1905 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAMES REGENERON PHARMACEUTICALS, INC.; BAYER HEALTHCARE LLC, APPLICATION NO. 2022275786, UNDER INID (72) ADD CO-INVENTORS EISSING, THOMAS KIRSCHBAUM; RITTENHOUSE, KAY D.

TH Corrigenda

Free format text: IN VOL 57 , NO 13 , PAGE(S) 1905 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME REGENERON PHARMACEUTICALS, INC.; BAYER HEALTHCARE LLC, APPLICATION NO. 2022275786, UNDER INID (72) CORRECT THE CO-INVENTOR TO EISSING, THOMAS

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 30 JUL 2025

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 04 SEP 2025

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 30 JUL 2025

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 04 SEP 2025

FGA Letters patent sealed or granted (standard patent)